BIVI Biovie Inc
Company Analysis
Latest News
🟢 Biovie is trading 6.14% up in pre-market after ending treatment in Phase 2 ADDRESS-LC trial
Biovie is trading 6.14% up at $2.42 after announcing on August 31, 2026, that treatment ended in its approximately 200-patient Phase 2 ADDRESS-LC trial of...
Biovie Insiders Put Their Own Money on the Line — But Can $49,000 in Purchases Signal Real Confidence in a $2 Stock?
Shares of Biovie Inc. (BIVI) jumped 11.6% to $2.41 on August 31 after SEC filings revealed that four company insiders — including the CEO — bought stock on the...
🟢 Biovie is trading 11.59% up today after four insiders bought shares
Biovie is trading 11.59% up at $2.41 after four insiders reported open-market purchases following the August 28 session. - CEO Cuong V. Do bought 15,210...
🟢 Biovie is trading 6.48% up in pre-market amid reported insider purchases
Biovie is trading at $2.30, up +6.48% in pre-market amid reported insider purchases. - Multiple insiders reported purchases after the August 28 session,...
🔴 Biovie is trading 5.21% down today amid unclear catalyst
Biovie is trading 5.21% down at $2.00, with no verified company-specific announcement identified on August 27, 2026, and the catalyst remains unclear. - Its...
🔴 Biovie is trading 5.21% down in pre-market; catalyst remains unclear
Biovie is trading 5.21% down at $1.98 in pre-market, with the catalyst unclear. - It closed at $2.09 on August 25, 2026. - Searches found no verified...
🔴 Biovie is trading 9.81% down today with no verified company-specific explanation
Biovie is trading 9.81% down at $1.93, with no verified company-specific announcement dated August 24 or August 25 explaining the decline. - The stock closed...
🔴 Biovie is trading 6.39% down in pre-market with no verified explanation for decline
Biovie is trading at $2.00, down 6.39% after closing at $2.14 on August 24, 2026; no verified announcement explains the decline. - No verified Biovie...
🔴 Biovie is trading 6.04% down today in after-hours trading as the immediate catalyst remains unclear
Biovie is trading 6.04% down at $2.01 after closing at $2.14 on August 24, 2026; the immediate catalyst remains unclear. - No verified company-specific...
🟢 Biovie is trading 7.69% up today with no clear catalyst identified
Biovie is trading 7.69% up at $2.10, with no clear catalyst identified for the move. - The stock is extending a highly volatile rebound after rising 38.81% on...
🔴 Biovie is trading 8.21% down today as Nasdaq falls 0.60%
Biovie is trading at $1.79 (-8.21%) during early August 24, 2026 trading amid broader risk-off pressure alongside a 0.60% Nasdaq loss. - The decline follows a...
🔴 Biovie is trading 6.15% down in pre-market
Biovie is trading at $1.83, down -6.15% in pre-market, with the immediate reason unclear. - No new company-specific announcement or earnings catalyst was...
🟢 Biovie is trading 25.38% up today after statistically significant Phase 2 SUNRISE-PD results
Biovie is trading 25.38% up at $2.33 after renewed investor attention to positive Phase 2 SUNRISE-PD results for bezisterim in early Parkinson’s disease. -...
🟢 Biovie is trading 11.38% up in pre-market after positive Phase 2 SUNRISE-PD results
Biovie is trading at $2.07, up 11.38% in pre-market after positive Phase 2 SUNRISE-PD results for bezisterim in early Parkinson’s disease. - The trial met its...
🟢 Biovie Inc is trading 6.45% up in pre-market
BIVI is trading at $1.98, up 6.45% in pre-market.
🟢 Biovie is trading 6% up in after-hours trading after positive Phase 2 SUNRISE-PD results
Biovie is trading at $1.97, up +6.12%, after positive Phase 2 SUNRISE-PD results for bezisterim. - The results extended its sharp August 20, 2026 rally and...
Biovie Inc Q2 2026 Earnings Preview: What Analysts Expect on August 21, 2026
Analysts expect BioVie Inc. to report a consensus revenue of $0.00 and an EPS loss of $0.52 for the second calendar quarter of 2026. The current stock price of...
Biovie's Parkinson's Drug Clears a Key Hurdle — But Can a $10 Million Company Really Deliver on a Blockbuster Promise?
Shares of BioVie Inc. surged 34.3% to $1.80 on August 20 as investors circled back to positive Phase 2 data for bezisterim, its experimental Parkinson's...
🟢 Biovie is trading 34.33% up today after positive Phase 2 SUNRISE-PD results
Biovie is trading 34.33% up at $1.80 after renewed attention to positive Phase 2 SUNRISE-PD results for bezisterim. - The trial reportedly met its primary...